ACS and STEMI treatment

gender-related issues.

Alaide Chieffo, Gill Louise Buchanan, Fina Mauri, Julinda Mehilli, Beatriz Vaquerizo, Anouska Moynagh, Roxana Mehran, Marie Claude Morice

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cardiovascular disease is the leading cause of death amongst women, with acute coronary syndromes (ACS) representing a significant proportion. It has been reported that in women presenting with ACS there is underdiagnosis and consequent undertreatment leading to an increase in hospital and long-term mortality. Several factors have to be taken into account, including lack of awareness both at patient and at physician level. Women are generally not aware of the cardiovascular risk and symptoms, often atypical, and therefore wait longer to seek medical attention. In addition, physicians often underestimate the risk of ACS in women leading to a further delay in accurate diagnosis and timely appropriate treatment, including cardiac catheterisation and primary percutaneous coronary intervention, with consequent delayed revascularisation times. It has been acknowledged by the European Society of Cardiology that gender disparities do exist, with a Class I, Level of Evidence B recommendation that both genders should be treated in the same way when presenting with ACS. However, there is still a lack of awareness and the mission of Women in Innovation, in association with Stent for Life, is to change the perception of women with ACS and to achieve prompt diagnosis and treatment.

Original languageEnglish
JournalEuroIntervention
Volume8 Suppl P
Publication statusPublished - Aug 2012

Fingerprint

Acute Coronary Syndrome
Interpersonal Relations
Therapeutics
Physicians
Percutaneous Coronary Intervention
Cardiac Catheterization
Stents
ST Elevation Myocardial Infarction
Cause of Death
Cardiovascular Diseases
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chieffo, A., Buchanan, G. L., Mauri, F., Mehilli, J., Vaquerizo, B., Moynagh, A., ... Morice, M. C. (2012). ACS and STEMI treatment: gender-related issues. EuroIntervention, 8 Suppl P.

ACS and STEMI treatment : gender-related issues. / Chieffo, Alaide; Buchanan, Gill Louise; Mauri, Fina; Mehilli, Julinda; Vaquerizo, Beatriz; Moynagh, Anouska; Mehran, Roxana; Morice, Marie Claude.

In: EuroIntervention, Vol. 8 Suppl P, 08.2012.

Research output: Contribution to journalArticle

Chieffo, A, Buchanan, GL, Mauri, F, Mehilli, J, Vaquerizo, B, Moynagh, A, Mehran, R & Morice, MC 2012, 'ACS and STEMI treatment: gender-related issues.', EuroIntervention, vol. 8 Suppl P.
Chieffo A, Buchanan GL, Mauri F, Mehilli J, Vaquerizo B, Moynagh A et al. ACS and STEMI treatment: gender-related issues. EuroIntervention. 2012 Aug;8 Suppl P.
Chieffo, Alaide ; Buchanan, Gill Louise ; Mauri, Fina ; Mehilli, Julinda ; Vaquerizo, Beatriz ; Moynagh, Anouska ; Mehran, Roxana ; Morice, Marie Claude. / ACS and STEMI treatment : gender-related issues. In: EuroIntervention. 2012 ; Vol. 8 Suppl P.
@article{2a30e393e4f64b418865072746573922,
title = "ACS and STEMI treatment: gender-related issues.",
abstract = "Cardiovascular disease is the leading cause of death amongst women, with acute coronary syndromes (ACS) representing a significant proportion. It has been reported that in women presenting with ACS there is underdiagnosis and consequent undertreatment leading to an increase in hospital and long-term mortality. Several factors have to be taken into account, including lack of awareness both at patient and at physician level. Women are generally not aware of the cardiovascular risk and symptoms, often atypical, and therefore wait longer to seek medical attention. In addition, physicians often underestimate the risk of ACS in women leading to a further delay in accurate diagnosis and timely appropriate treatment, including cardiac catheterisation and primary percutaneous coronary intervention, with consequent delayed revascularisation times. It has been acknowledged by the European Society of Cardiology that gender disparities do exist, with a Class I, Level of Evidence B recommendation that both genders should be treated in the same way when presenting with ACS. However, there is still a lack of awareness and the mission of Women in Innovation, in association with Stent for Life, is to change the perception of women with ACS and to achieve prompt diagnosis and treatment.",
author = "Alaide Chieffo and Buchanan, {Gill Louise} and Fina Mauri and Julinda Mehilli and Beatriz Vaquerizo and Anouska Moynagh and Roxana Mehran and Morice, {Marie Claude}",
year = "2012",
month = "8",
language = "English",
volume = "8 Suppl P",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",

}

TY - JOUR

T1 - ACS and STEMI treatment

T2 - gender-related issues.

AU - Chieffo, Alaide

AU - Buchanan, Gill Louise

AU - Mauri, Fina

AU - Mehilli, Julinda

AU - Vaquerizo, Beatriz

AU - Moynagh, Anouska

AU - Mehran, Roxana

AU - Morice, Marie Claude

PY - 2012/8

Y1 - 2012/8

N2 - Cardiovascular disease is the leading cause of death amongst women, with acute coronary syndromes (ACS) representing a significant proportion. It has been reported that in women presenting with ACS there is underdiagnosis and consequent undertreatment leading to an increase in hospital and long-term mortality. Several factors have to be taken into account, including lack of awareness both at patient and at physician level. Women are generally not aware of the cardiovascular risk and symptoms, often atypical, and therefore wait longer to seek medical attention. In addition, physicians often underestimate the risk of ACS in women leading to a further delay in accurate diagnosis and timely appropriate treatment, including cardiac catheterisation and primary percutaneous coronary intervention, with consequent delayed revascularisation times. It has been acknowledged by the European Society of Cardiology that gender disparities do exist, with a Class I, Level of Evidence B recommendation that both genders should be treated in the same way when presenting with ACS. However, there is still a lack of awareness and the mission of Women in Innovation, in association with Stent for Life, is to change the perception of women with ACS and to achieve prompt diagnosis and treatment.

AB - Cardiovascular disease is the leading cause of death amongst women, with acute coronary syndromes (ACS) representing a significant proportion. It has been reported that in women presenting with ACS there is underdiagnosis and consequent undertreatment leading to an increase in hospital and long-term mortality. Several factors have to be taken into account, including lack of awareness both at patient and at physician level. Women are generally not aware of the cardiovascular risk and symptoms, often atypical, and therefore wait longer to seek medical attention. In addition, physicians often underestimate the risk of ACS in women leading to a further delay in accurate diagnosis and timely appropriate treatment, including cardiac catheterisation and primary percutaneous coronary intervention, with consequent delayed revascularisation times. It has been acknowledged by the European Society of Cardiology that gender disparities do exist, with a Class I, Level of Evidence B recommendation that both genders should be treated in the same way when presenting with ACS. However, there is still a lack of awareness and the mission of Women in Innovation, in association with Stent for Life, is to change the perception of women with ACS and to achieve prompt diagnosis and treatment.

UR - http://www.scopus.com/inward/record.url?scp=84905300592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905300592&partnerID=8YFLogxK

M3 - Article

VL - 8 Suppl P

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

ER -